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INTRODUCTION
Calcium and vitamin D are metabolically interrelated to serve endocrine functions. Vitamin D, as the active metabolite (1,25-dihydroxyvitamin D [1, 25(OH) 2 D] ) 4 , forms part of the endocrine system that maintains serum calcium concentrations, which are required for bone mineralization (1) and several nonskeletal processes (2) . Interactions between vitamin D and calcium may have implications for the regulation of serum 25-hydroxyvitamin D [25(OH)D] concentrations and its catabolism and, consequently, the dietary vitamin D requirement. For example, if dietary calcium intake is low, and serum calcium concentrations decrease, the compensatory metabolic response is an accelerated conversion of 25(OH)D to 1,25(OH) 2 D [via parathyroid hormone (PTH)], which normalizes serum calcium concentrations. There have been animal data that suggested that the plasma half-life of 25(OH)D will be reduced by low calcium intake accompanied by an increased hepatic conversion of 25(OH)D to metabolites, which are excreted in bile (3) . Mechanistically, the increased synthesis of 1,25(OH) 2 D during times of low calcium intakes induces the synthesis of the 24-hydroxylase enzyme, which converts serum 25(OH)D to 24,25-dihydroxyvitamin D [24, 25(OH) 2 D] . In vitro experiments with purified 24-hydroxylase suggested that 24-hydroxylation is just the first step in a 5-step, vitamin D-inducible pathway to water-soluble truncated degradation products (4) . However, older animal data suggested that 24,25(OH) 2 D [and its metabolite 1,24,25-trihydroxyvitamin D] may stimulate intestinal calcium absorption and bone calcium mobilization (5, 6) , suggesting a biological activity in addition to a role in the degradation of vitamin D. The use of intravenously administered radiolabeled 25(OH)D in patients has shown that its elimination half-time in plasma was significantly shortened by oral 1,25(OH) 2 D treatment (7). There has also been supportive evidence from children with calcium-responsive rickets for a low calcium intake-induced enhanced catabolism of 25(OH)D (8) .
Although such perturbations may confound the estimation of the true requirement for vitamin D, this effect has received relatively little research attention to date in healthy humans. Of particular note, Dietary Reference Intakes (DRIs) recently reported for calcium and vitamin D highlighted that the elucidation of the interrelationships between calcium and vitamin D and the examination of the influence of calcium intake on the regulation of vitamin D activation and catabolism are key information gaps (9) . Even within the relatively limited data that exist, there has been ambiguity. Calcium intake has been reported as a significant determinant of serum 25(OH)D in some (10) (11) (12) (13) but not all (14, 15) observational studies. One randomized controlled trial (RCT) in healthy men reported a large increase (30%) in serum 25(OH)D in subjects supplemented with calcium than in subjects with normal calcium intakes (16) , whereas 2 other RCTs showed no effect of additional calcium on serum 25(OH)D in healthy adults (17, 18) . However, caution is needed because all 3 RCTs had design characteristics that may have affected the interpretation of their findings in relation to vitamin D DRIs. For example, vitamin D DRIs have been established for the wintertime (9) when serum 25(OH)D concentrations naturally decline, which is a design consideration that none of the 3 RCTs addressed, and the adequacy of serum 25(OH)D may influence 1,25(OH) 2 D (19, 20) , which, in turn, influences 24-hydroxylase.
Thus, the aim of this study was to perform a randomized, controlled, vitamin D 3 intervention study in apparently healthy, free-living adults (aged $50 y) to investigate whether different concentrations of habitual calcium intake, ranging from moderatelow to high intakes, influence serum 25(OH)D concentrations and indexes of vitamin D activation and catabolism as explanatory variables during winter when vitamin D intake is adequate compared with inadequate.
SUBJECTS AND METHODS

Subjects
A total of 125 apparently healthy, free-living adults aged $ 50 y were recruited in this 15-wk vitamin D 3 intervention trial. Subjects were recruited in the Cork area through the use of advertisements placed around University College Cork and across the location as well as on radio. We aimed to recruit a ratio of w2.5:1 women to men because this is the ratio of women to men (aged $50 y) with moderate-low (,700 mg/d; see Design and conduct of study) calcium intakes as reported in the National Adult Nutrition Survey in Ireland (21) and the National Diet and Nutrition Survey in the United Kingdom (22) . White men and women aged $50 y who provided consent were included in the study. Volunteers were excluded if they were unwilling to discontinue the consumption of vitamin D-containing supplements 4 wk before the initiation of the study and throughout the study. Volunteers were also excluded if they planned to take a winter vacation (during the course of the 15-wk intervention) to a location where either the altitude or the latitude was predicted to result in significant cutaneous vitamin D synthesis from solar radiation (eg, a winter-sun coastal resort or a mountain ski resort) or if they used tanning facilities of any type. A severe medical illness, hypercalcemia, known intestinal malabsorption syndrome, excessive alcohol use, and the use of medications known to interfere with vitamin D metabolism were also reasons for exclusion. The study was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals, University College Cork. All participants gave their written consent according to the Helsinki Declaration. This trial was registered at clinicaltrials.gov as NCT01990872.
Design and conduct of study
The study was a double-blind, placebo-controlled trial in which older adults, who were stratified according to calcium intakes (moderate-low or high intake), were randomly assigned to receive a capsule that contained a placebo or 20 mg vitamin D 3 /d for 15 wk throughout the winter. During the recruitment phase, subjects were initially screened for their habitual intake of calcium (and vitamin D) via a validated food-frequency questionnaire (23, 24) that was administered by a research nutritionist. For the purposes of this study, moderate-low calcium intake was defined as ,700 mg/d, whereas high calcium intake was defined as .1000 mg/d. The reference nutrient intake and population reference intake value for calcium in the United Kingdom and European Union, respectively, is700 mg/d (25, 26) , and w49% and w69% of UK men and women (aged 50-64 y), respectively, have calcium intakes below this value (22) . The European Union estimated average requirement (EAR) for calcium is 550 mg/d (26) and w5 and w15% of men and women, respectively, in the United Kingdom have intakes below this value (22) . In relation to high calcium intake, the North American Institute of Medicine (IOM) has suggested that EAR and Recommended Dietary Allowance (RDA) values for calcium in women aged .50 y and men aged .70 y are 1000 and 1200 mg/d, respectively (9) . For men aged 50-70 y, the RDA is 1000 mg Ca/d (9) . In addition, for the purposes of informing the design of the current study, we revisited our recent meta-analysis of the relation of vitamin D intake to serum 25(OH)D, which used data from RCTs performed at latitudes .508 (27) , and included data on average habitual calcium intake from each of the studies. Stratification of the 11 RCTs by the median (w1000 mg/d) of reported average calcium intakes in these studies showed that there was a significant (P , 0.05) interaction between calcium intake (.1000 or ,1000 mg/d) and vitamin D intake such that subjects with lower calcium intakes had a less-steep slope [response of serum 25(OH)D] than did subjects with higher calcium intakes (the 2 slopes were significantly different; 0.030 compared with 0.044, respectively; P = 0.023; unpublished data). Therefore, the achievement of a serum 25(OH)D concentration of 50 nmol/L required lower vitamin D intake in subjects with a higher calcium intakes (.1000 mg/d) than in subjects with lower intake (,1000 mg Ca/d).
To maximize the subject recruitment in the study, any subject (n = 38) whose habitual calcium intake was .700 mg/d but did not reach the .1000-mg/d target was asked during recruitment if they would take additional calcium. Subjects were given a choice as to whether they wished to consume the additional calcium in the form of a supplement [one Calcichew tablet that contained 500 mg Ca alone (Shire Pharmaceuticals Ireland Ltd); n = 36 opted for this route] or as additional milk in their diet (n = 2 opted for this route), so that their calcium intakes would be .1000 mg/d for the duration of the intervention phase. These additional calcium intakes were started 4 wk before the intervention phase commenced to allow for normalization of calcitropic hormone concentrations (28) .
The IOM has suggested that the RDA-like serum 25(OH)D concentration required to meet the needs of 97.5% of the population aged $1 y is 50 nmol/L (9 (21) , would provide about w25 mg/d in the current study.
The random assignment of subjects was centralized and computer generated and accounted for calcium intake grouping (moderate-low or high intakes) and sex. Vitamin D 3 Compliance was assessed by capsule counting. An a priori decision was made to include only subjects who exceeded 80% compliance. The allocation remained concealed until final analyses, and all outcomes were reported by people masked to the allocation scheme.
The study was carried out in Cork, Republic of Ireland (latitude: 518N). All subjects were screened, recruited, and commenced the intervention study between 5 and 23 November 2012 and finished the study 15 wk later between 18 February and 14 March 2013, during which the vitamin D status would be expected to decline to a nadir (31) . During the intervention phase, each participant was met by researchers on 3 occasions at the study center, once each at baseline (week 0), week 8 (which was close to the midpoint), and the endpoint (week 15) of the study. At each visit, an overnight fasting blood sample was taken from each participant between 0830 and 1030 by a trained phlebotomist. Blood was collected by venipuncture into an evacuated tube with no additive and processed to serum, which was immediately stored at 2808C until required for analysis. Anthropometric measures, including height and weight, were taken as described previously (32) . A health and lifestyle questionnaire, which assessed physical activity, general health, smoking status, and alcohol consumption, was completed at baseline. Participants were contacted regularly by phone or correspondence to promote compliance and encourage the completion of the study protocol. D 3 ] in all serum samples were measured by the Vitamin D Research Group at University College Cork by using a liquid chromatography-tandem mass spectrometry (LC-tandem MS) method that has been described in detail elsewhere (33) . The quality and accuracy of the serum 25(OH)D analysis by using the LC-tandem MS in our laboratory is monitored on an ongoing basis by participation in the Vitamin D External Quality Assessment Scheme (Charing Cross Hospital). In addition, the Vitamin D Research Group is a participant in the Vitamin D Standardization Program (34) and Vitamin D Standardization Certification Program (35) .
Laboratory analysis
Serum 25(OH)D
Concentrations of total 25(OH)D [ie, 25(OH)D 2 plus 25(OH)
Serum intact PTH
Serum PTH concentrations were measured at University College Cork in all serum samples by using an ELISA (Intact PTH; MD Biosciences Inc). Intraassay and interassay CVs were 3.4% and 3.8%, respectively.
Serum total calcium
Total calcium and albumin concentrations in all serum samples were measured at Cork University Hospital, Cork, Ireland. Serum calcium concentrations were adjusted for albumin concentrations. (36) . Therefore, we calculated the concentration of free 25(OH)D by using a previously described equation (37) . The ratio of 24,25(OH) 2 
Statistical analysis
Berlin and Bjorkhem (16) 2 D were not normally distributed and, thus, were either log or square-root transformed to achieve near-normal distributions. Serum concentrations of 25(OH)D, albumin-corrected calcium, DBP, the 24,25(OH) 2 D:25(OH)D ratio as well as age, weight, height, BMI, and dietary calcium were normally distributed. Baseline characteristics of men and women were compared by using unpaired Student's t tests. Baseline characteristics of subjects in the different intervention groups were compared by using the chi-square test (for the ratio of men to women) and 1-factor ANOVA. Linear models of the response in a repeated-measures analysis for differences in serum 25(OH)D, albumin-corrected calcium, PTH, 24,25(OH) 2 , and these were reported. If no significant calcium intake grouping 3 vitamin D treatment 3 time interaction was observed, then calcium intake grouping 3 time and vitamin D treatment 3 time interactions were explored. Models were also run to include sex as an additional factor. Bonferroni-adjusted t tests were used for post hoc analysis to the ANOVA. P , 0.05 was taken as being statistically significant.
RESULTS
Baseline characteristics of subjects
Of 125 subjects recruited onto the study, 121 subjects completed the intervention. The progress of these subjects through the trial is shown in Figure 1 . Baseline characteristics of subjects who entered the intervention are shown in Table 1 . Although women were, on average, lighter and smaller than men (both P , 0.0001) and had lower serum 1,25(OH) 2 placebo and vitamin D 3 with high-calcium intake groups) (data not shown). Similarly, there was no significant difference in the proportion of men to women in treatment groups ( Table 2) . Mean habitual dietary vitamin D was significantly (P = 0.01) higher in the group with high calcium intake who were randomly assigned to receive vitamin D supplementation than in the group with moderate-low calcium intake who were randomly assigned to receive the placebo, but otherwise there was no significant difference (Table 2 ). Mean habitual dietary calcium was similar in the 2 groups with moderate-low calcium intakes and similar in the 2 groups with high calcium intakes, with the latter 2 groups with significantly higher calcium (P , 0.0001) than for the former 2 groups (Table 2 ). Mean total calcium intakes (habitual plus additional calcium intakes) for the 2 groups with high calcium intakes are shown in Table 2 , and these intakes were similar (P . 0.7).
There were no adverse events reported during the study. Of 4 dropouts, 2 subjects were in the period between baseline and midpoint samplings (1 subject was from the group with moderate-low calcium intake plus 20 mg vitamin D 3 /d, 1 subject was from the group with high calcium intake plus the placebo), and 2 subjects (both from the group with high calcium intake plus 20 mg vitamin D 3 /d) were in the period between midpoint and endpoint samplings. Dropout during the intervention phase was for reasons of unavailability or loss of interest, and in no instance was dropout related to the intervention. There was good supplement adherence on the basis of the pill count ([median (IQR) compliance was 98.6% (94.3%, 100%), compliance was similar in the 4 treatment groups; P = 0.9].
Effects of vitamin D treatment in the 2 calcium intake groupings (moderate-low compared with high intakes) on serum 25(OH)D, albumin-corrected calcium, and PTH at the baseline, midpoint, and endpoint are shown in Table 2 . There was no significant difference in preintervention serum 25(OH)D concentrations in treatment groups (Table 2) . A repeated-measures ANOVA showed that there was no significant (P = 0.2) time 3 vitamin D treatment 3 calcium intake grouping interaction effect on mean serum 25(OH)D concentration over the 15-wk intervention period (Table 2) . Likewise, there was no significant (P = 0.8) time 3 calcium intake grouping interaction effect, but there was a significant (P # 0.0001) time 3 vitamin D treatment interaction effect on mean serum 25(OH)D concentration over the 15-wk intervention period (Table 2) . Because calcium intake grouping had no effect, the mean (6SD) baseline serum 25 There was no significant interaction between time 3 vitamin D treatment 3 calcium intake grouping (or time 3 vitamin D treatment or time 3 calcium intake grouping) and sex (all P .
0.4) in the response of serum 25(OH)D to the intervention (data not shown).
There was no significant difference in preintervention serum albumin-corrected calcium concentrations in treatment groups (Table 2 ). There was no significant time 3 vitamin D treatment 3 calcium intake grouping interaction effect or time 3 vitamin D treatment or time 3 calcium intake grouping interaction effects (all P . 0.3) on mean serum albumin-corrected calcium concentrations over the 15-wk intervention period.
A repeated-measures ANOVA showed that there was a significant (P , 0.05) difference in preintervention serum PTH concentrations in groups stratified by calcium intakes. The 2 groups with moderate-low calcium combined (n = 56) had a modest but significantly (P = 0.037) higher median (IQR) baseline serum PTH than did the 2 groups combined (n = 69) who had a high calcium intake [50.2 pg/mL (38.2, 67.6 pg/mL) compared with 43.9 pg/mL (34.7, 55.9 pg/mL), respectively]. There was no significant (P = 0.3) time 3 vitamin D treatment 3 calcium intake grouping interaction effect on the median (IQR) serum PTH concentration over the 15-wk intervention period (Table 2) . Likewise, there was no significant (P = 0.7) time 3 calcium intake grouping interaction effect, but there was a significant (P = 0.013) time 3 vitamin D treatment interaction effect on the median (IQR) serum PTH concentration over the 15-wk intervention period (Table 2) . Median serum PTH concentrations in the 2 groups who received 20 mg vitamin D 3 /d, irrespective of the calcium intake grouping, remained unchanged (P . 0.3) over the 15 wk, whereas median serum PTH concentrations in the 2 groups who received the placebo, irrespective of the calcium intake grouping, remained unchanged (P . 0.7) over the first 8 wk but had increased significantly (P = 0.034) by week 15 [44.8 pg/mL (35.2, 56.9 pg/mL), 45.1 pg/mL (40.1, 58.4 pg/mL), and 47.8 pg/mL (49.0, 57.1 pg/mL), respectively].
Effects of vitamin D treatment in the 2 calcium intake groupings (moderate-low compared with high intakes) on the Table 3 . There was no significant difference in preintervention concentrations for any of these variables in treatment groups (Table 3) . A repeated-measures ANOVA showed that there was no significant (P . 0.1 for all) time 3 vitamin D treatment 3 calcium intake grouping interaction effect on the mean serum 24,25(OH) 2 (Table 3) . Because the calcium intake grouping had no effect, the mean baseline 24,25(OH) 2 In terms of within-combined-treatment-group changes from the baseline to endpoint, mean and median serum 24,25(OH) 2 D, ratio of 24,25(OH) 2 D:25(OH)D, and free 25(OH)D concentrations in combined groups who received the placebo (n = 60), irrespective of the calcium intake grouping, decreased significantly from weeks 0-15 (by 54.5%, 28.6%, and 24.3%, respectively; P # 0.0001 for all), whereas there was no significant change (P = 0.4) in the median serum 1,25(OH) 2 (9, 40, 41, 43) will ensure the adequacy of serum 25(OH)D concentrations in older adults even when calcium intakes of these adults are in the inadequate range (,700 mg/d, and possibly even ,550 mg/d). The winter-based, 2 3 2 factorial design of the current vitamin D 3 intervention study differed from the designs of the limited number of previous RCTs in this area (16) (17) (18) . The design allowed us to assess the possible interaction effect of 2 different nutritionally and public health-relevant calcium intake bands (ie, ,550 and ,700 compared with .1000 mg/d) on the natural decline in serum 25(OH)D concentrations that are a result of absent or markedly diminished UVB sunlight as well as on the potential of an adequate vitamin D intake in maintaining serum 25(OH)D concentrations $50 nmol/L (6) during winter. Berlin and Bjorkhem (16) reported that the supplementation of healthy young adult men (n = 14/group) with 2000 mg Ca/d in addition to the usual diet for 6-7 wk during late autumn and early winter in Sweden led to a significant increase in serum 25(OH)D concentrations (by 30%) relative to that in a control group who consumed a normal diet. Unfortunately, the habitual dietary intake of calcium was not assessed in the study, but the authors worked on the assumption that it was w800 mg/d (16) . Although none of the subjects received vitamin D supplementation, serum 25(OH) D concentrations increased in both calcium and control groups over the 6-7-wk study period (increasing from a mean of 67-71 nmol/L in the control group) that was from late October to early December (16) . Of note, the authors suggested that their unpublished data on an identical trial that was conducted from The IOM used data from winter-based RCTs with vitamin D alone to establish the DRI for vitamin D (9) . This method was used because of the concern that altering calcium intake as well as vitamin D intake in RCTs may affect serum 25(OH)D concentrations because of the altered regulation of vitamin D activation and catabolism. All calcium-supplemented subjects in the 3 RCTs previously mentioned (16) (17) (18) had increases in their usual calcium intake of the order of an additional 1000-2000 mg Ca/d, which likely brought their total mean calcium intakes into the range from .1500 to .2700 mg/d. This perturbation in calcium intake alone may have altered calcitropic hormone concentrations from the baseline to endpoint. One study showed a significant reduction in serum 1,25(OH) 2 D (but not PTH) with calcium supplementation (16), whereas 1,25(OH) 2 D (17, 18) and, surprisingly, PTH (17) were unaffected by calcium supplementation in the other studies. Responses of these hormones to interventions have been variable (17) . In the current study, we tried to minimize the perturbation of usual calcium intake and possible knock-on effects on calcitropic hormones by stratifying subjects at recruitment by habitual calcium intake, and only in subjects (n = 38) who fell short of the cutoff for high calcium intake (.1000 mg/d) did we add supplemental calcium to meet this target [started 4 wk before baseline to facilitate normalization of calcitropic hormone concentrations (28) ]. In the comparison of subjects with ,550 and .1000 mg Ca/d, there was no perturbation because these were all habitual intakes of calcium. Thus, declines and increases in serum 25(OH)D over the winter, which were associated with inadequate and adequate dietary vitamin D, respectively, were compared in subjects with their habitual low calcium intakes and their habitual, or as close as, high calcium intakes.
With the use of the 24,25(OH) 2 (4, 19, 38) , the lack of effect of the concentration of habitual intake of calcium on the response of both variables during the current study was in keeping with the main findings of a lack of interaction between calcium and vitamin D on the response of serum 25(OH)D. In contrast, supplementation with vitamin D 3 significantly increased the serum 24,25(OH) 2 (3, 7) , whereas it appears less clear whether PTH itself has an independent effect on the catabolism of 25(OH)D (3). Vitamin D 3 supplementation during winter had no effect on serum PTH in the current study but significantly increased serum 1,25(OH) 2 D concentrations. Although serum 1,25(OH) 2 D was not increased by vitamin D supplementation in some RCTs (17, 18) , it has been increased in other studies (44) . The serum 24,25(OH) 2 D concentration and ratio of 24,25(OH) 2 D:25(OH)D were significantly reduced during winter in placebo groups, which suggested a possible 24-hydroxylase-mediated sparing effect aimed at maintaining serum 25(OH)D even though concentrations, as expected, decreased during the winter. Although serum PTH was significantly increased over the wintertime in placebo groups, serum 1,25(OH) 2 D was unchanged.
Although the current study did not include an entire group of subjects with extremely low calcium intakes, in whom an effect on serum 25(OH)D catabolism might have occurred and, thus, may have been a potential limitation of the study, 50% of subjects in the moderate-low calcium intake grouping had intakes ,550 mg Ca/d, 25% of subjects had intakes ,400 mg Ca/d, and all subjects had intakes ,700 mg Ca/d. Within the population, only 3% and 13% of Irish adults have calcium intakes ,400 and ,550 mg/d, respectively (21) .
In conclusion, the findings of the current study suggest that responses in serum 25(OH)D (both bound and free) concentrations throughout winter as well as indexes of vitamin D activation and catabolism were similar in older adults irrespective of whether they had relatively low or high habitual calcium intakes. Thus, recent dietary vitamin D-requirement estimates will cover the vitamin D needs of even those individuals who do not have adequate calcium intakes.
